When Will Generic Ozempic Be Available in the US?

Short answer: not before the end of 2031, and realistically later than that.

That is a frustrating answer, especially since generic semaglutide is already being sold in India for the equivalent of a few dollars a week and has been approved in Canada, right across the border. The gap is not about science or manufacturing. It is about how US drug patents work.

This article explains the timeline, why other countries got there first, what “generic” actually means in this context, and what lower-cost options exist for Americans in the meantime. None of it is medical advice, and nothing here should be read as encouragement to buy medicine from unapproved sources.

What is the actual US patent expiry date?

Semaglutide’s core US patents, as listed in the FDA’s Orange Book, expire December 5, 2031 and December 16, 2031 [1]. Additional patents covering formulations and delivery devices for Wegovy and Rybelsus run later.

Novo Nordisk first applied for a US patent on semaglutide in 2006. A standard US patent runs 20 years from filing, which would have put expiry in 2026. Patent term extensions, granted to compensate for time lost during FDA review, pushed it out roughly five more years [2].

Reporting and analyst models generally land in the same place: NBC News reported in May 2026 that approved generic semaglutide is not expected in the US “until at least the end of 2031” [2], and several analyses model practical entry in 2032 or 2033 once patent litigation over secondary patents is resolved.

So the honest range is: earliest possible late 2031, more likely 2032 to 2033.

Why did India and Canada get generics first?

Because their patents expired first, and for slightly different reasons in each case.

India. Novo Nordisk’s core Indian patent lapsed on March 20, 2026 [8]. Within days, more than a dozen manufacturers launched generic semaglutide. Dr. Reddy’s launched a pen called Obeda at about 4,200 rupees per month. Sun Pharma launched at prices reported as low as 750 rupees (about $8) per weekly injection. Zydus, Alkem, Glenmark, Natco, Cipla and others followed [8][9]. By April 2026 more than 40 approved generic semaglutide brands were reported in circulation, with the cheapest vial formats starting around 325 rupees per weekly injection [10].

For context, Novo Nordisk’s own Indian price had been roughly 8,800 to 10,000 rupees per month depending on dose, before the company cut prices in response [9].

Canada. Canadian data exclusivity on semaglutide expired January 4, 2026 [7]. On April 28, 2026, Health Canada authorized its first generic semaglutide injection, filed by Dr. Reddy’s Laboratories as a generic of Ozempic, making Canada the first G7 country to approve generic semaglutide [21]. A second generic, from Canadian manufacturer Apotex, followed on May 1, 2026, with seven further submissions under review at that point [5]. On June 30, 2026, Health Canada approved the first generic semaglutide indicated for weight loss [22]. On May 21, 2026, the US telehealth company Hims & Hers began offering Apotex-made generic semaglutide to Canadian customers, its first international generic GLP-1 offering [6]. Sandoz told Reuters it expected to launch unbranded semaglutide in Canada by the end of June 2026 and has said it would price generics as much as 70% below the brand [7].

The difference comes down to patent term extensions. Several of these countries either did not offer them at the time semaglutide was filed or offered shorter ones, so the clock ran out sooner.

Is generic semaglutide a “generic” or a “biosimilar”?

This trips people up, and the answer affects the timeline.

Biologic drugs, like insulin or antibody therapies, go through a biosimilar pathway that is slower and more expensive than the generic pathway. Small molecules go through the abbreviated new drug application, or ANDA, pathway, which is faster.

Semaglutide is a peptide of 31 amino acids. The FDA treats peptide chains under 40 amino acids as candidates for the generic pathway rather than the biosimilar pathway, which means US generic semaglutide would be filed as an ANDA and would generally not require new human clinical trials if the company can show chemical equivalence [4]. European rules differ: synthetic semaglutide would be treated as a generic there while a recombinant version would be treated as a biosimilar [4].

The practical implication is that the US bottleneck is patents, not regulatory science.

Are companies already lining up?

Yes, and they have been for a while.

FDA data cited by Chemical & Engineering News show that at least 13 companies have contacted the agency about selling generic semaglutide in the US [3]. The first company to file a valid application challenging the patents gets a 180-day period of marketing exclusivity, which is a substantial financial prize and a strong incentive to file early [3].

There has already been at least one tentative approval. Reporting in 2026 indicates that Apotex and Orbicular received tentative FDA approval for a generic semaglutide injection [15]. Tentative approval means the FDA found the application acceptable on quality, safety and efficacy grounds, but the product cannot be marketed while patents remain in force. It is a placeholder, not a launch.

Litigation is also under way. Reporting indicates Cipla filed an abbreviated new drug application challenging semaglutide patents and that Novo Nordisk responded with a patent infringement lawsuit in July 2026 [15]. Treat that as reported rather than confirmed from a court docket until it can be verified directly.

What about generic Wegovy, Zepbound and Mounjaro?

Wegovy. Wegovy is also semaglutide, so it faces the same compound patent timeline plus additional patents covering the higher-dose presentations. No US generic Wegovy is expected before the semaglutide patents lapse.

Mounjaro and Zepbound. These contain tirzepatide, a different molecule entirely, with later patents. First US patents covering tirzepatide expire in 2036 [11].

That has not stopped filings. On June 29, 2026, the FDA accepted two abbreviated new drug applications from Sandoz for a generic tirzepatide autoinjector, covering all indications of both Mounjaro and Zepbound [11][12]. Sandoz developed the product in-house and says it could be among the first generic tirzepatide products available in the US “on market formation” [11]. Acceptance means a review has started. It does not mean a launch is near.

Is there a generic GLP-1 you can get in the US today?

Yes, one: liraglutide.

• The FDA approved the first generic of Victoza (liraglutide for type 2 diabetes), from Hikma Pharmaceuticals, on December 23, 2024; generics from Meitheal and Lupin followed [14].
• On August 28, 2025, Teva won FDA approval for and launched a generic of Saxenda (liraglutide for chronic weight management in adults and in adolescents aged 12 to 17), the first generic GLP-1 approved for an obesity indication in the US [13][19]. Cipla has also launched a generic Saxenda.

An older generic, exenatide, is also available [14].

Important caveat: liraglutide is not interchangeable with semaglutide or tirzepatide. It is a daily injection rather than weekly, and it produced substantially less weight loss in trials. It is a real option worth discussing with a provider, not a substitute.

Is compounded semaglutide the same as a generic?

This distinction matters more than almost anything else on this page.

A generic is an FDA-approved product. The manufacturer must demonstrate that it contains the same active ingredient, in the same amount, and that it behaves the same way in the body as the brand. The FDA inspects the facility and reviews the data.

A compounded product is prepared by a pharmacy. It is not FDA approved, no bioequivalence has been demonstrated, and oversight comes primarily from state boards of pharmacy rather than the FDA’s drug approval process. Compounded semaglutide became widely available during the shortage years, and the rules around it have shifted as shortages resolved.

Anyone considering a compounded product should understand that it is a legally and clinically different thing from a generic and should discuss it with a healthcare provider and pharmacist. Our compounding coverage goes into the current rules in more detail.

What can actually lower your cost right now?

Waiting until 2032 is not a plan. Several things changed in 2025 and 2026 that are available today.

Manufacturer self-pay pricing. Both companies now sell direct to cash-paying patients, and in both cases the advertised “starting at” price is the lowest dose, not what most people pay long term.

• Foundayo through LillyDirect lists $149 per month for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg, with the two highest doses at $299 if refilled within 45 days under the Self Pay Journey Program. Through December 31, 2026 Lilly is temporarily discounting the 2.5 mg dose to $149 and the 5.5 mg dose to $199 [17][24].
• The Wegovy pill through NovoCare Pharmacy is $149 per month for 1.5 mg, $199 for 4 mg and $299 for the 9 mg and 25 mg doses. The 25 mg dose is the approved weight-management maintenance dose, so $299 is the figure to plan against [23].
• Zepbound self-pay starts at $299 per month, and the Wegovy pen is $349 per month for self-pay patients after an introductory $199 for the first two months of the two lowest doses [18][23].

A list-price cut is coming. On February 24, 2026 Novo Nordisk announced that effective January 1, 2027 it will lower the US list price, or wholesale acquisition cost, of Wegovy, Ozempic and Rybelsus to $675 per month — roughly a 50% cut for Wegovy and 35% for Ozempic [20]. List price is the sticker figure before rebates and is not what most people pay at the counter, and Novo has said the change does not lower the self-pay prices above. It matters mainly for people whose cost sharing is calculated from list price, such as those in high-deductible plans or with coinsurance.

Commercial insurance savings cards. Eligible people with commercial insurance may pay as little as $25 per month for Foundayo [17]. Similar programs exist for other brands, with eligibility rules that generally exclude people on government insurance.

Most-favored-nation pricing and TrumpRx. On November 6, 2025 the White House announced agreements with Eli Lilly and Novo Nordisk setting Medicare payment at about $245 per month for GLP-1 drugs with a $50 patient copay, plus discounted cash prices through a government platform launched in January 2026 [16].

Medicare GLP-1 Bridge. This program went live July 1, 2026 and lets eligible Medicare Part D beneficiaries get certain approved weight-loss drugs, including Foundayo, Wegovy and the Zepbound KwikPen, for $50 per month. It runs through December 31, 2027 and requires meeting CMS criteria including a qualifying BMI and prior authorization [17][18].

Generic liraglutide, as described above.

Prices and eligibility change frequently. Verify current terms directly with the manufacturer, your plan or your pharmacist before budgeting.

Should you try to import from Canada or India?

This comes up constantly, and the honest answer is that it is complicated and risky.

The generics approved in Canada and India are legitimate medicines in those countries, made by large manufacturers under those regulators’ rules. That is not the issue. The issues are:

1. Legal. Personal importation of prescription drugs into the United States is legally restricted. Some narrow exceptions exist, but they do not amount to a general permission to buy foreign medicine by mail.
2. Verification. Once you are buying from a website rather than a licensed pharmacy in that country, you have no reliable way to know what you are receiving. Counterfeit GLP-1 products have been a documented problem.
3. Continuity of care. Prescription medicines in this class involve dose titration and side-effect management. Buying outside a care relationship removes the person who is supposed to help with that.

If cost is the barrier, the more productive conversation is with a healthcare provider or pharmacist about the programs listed above, about whether a different approved drug is covered by your plan, and about patient assistance programs.

What to watch next

Three things will move this timeline:

1. Patent litigation. If a generic manufacturer successfully challenges Novo Nordisk’s secondary patents, entry could come sooner than 2032. If Novo Nordisk successfully defends them, it could come later.
2. Next-generation drugs. Novo Nordisk’s own strategy is to have successors ready before semaglutide goes off patent. CagriSema was filed with the FDA in December 2025, and IQVIA has noted that survodutide from Boehringer Ingelheim could be a third entrant in that space [4]. New branded drugs do not lower the price of old ones, but they do change what payers cover.
3. Policy. The most-favored-nation framework and Medicare programs have already done more to lower US out-of-pocket costs in 2026 than generic entry will do before 2032.

For now, the practical answer stands: generic semaglutide is real, it exists in other countries, and Americans are waiting until the 2030s for an approved version here. In the meantime, the cheapest legitimate route runs through manufacturer programs, insurance coverage and a conversation with a provider, not through the internet.

Sources

1. Drugs.com, “Generic Ozempic Availability & Release Date” — https://www.drugs.com/availability/generic-ozempic.html
2. NBC News, “Cheaper generic Ozempic is coming soon, but not for Americans” — https://www.nbcnews.com/health/health-news/generic-ozempic-united-states-limitation-drug-patents-india-canada-rcna344737
3. Chemical & Engineering News, “Looming GLP-1 drug patent expirations draw generics firms” — https://cen.acs.org/pharmaceuticals/Looming-GLP-1-drug-patent/103/web/2025/12
4. IQVIA, “Your Questions Answered: Off-patent Semaglutide in 2026” — https://www.iqvia.com/locations/emea/blogs/2026/04/your-questions-answered-off-patent-semaglutide-in-2026
5. Health Canada, “Canada approves second generic semaglutide, the first G7 country to do so” — https://www.canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html
6. Reuters, “Hims offers Apotex’s generic semaglutide in Canada after Novo patent expiry” — https://www.reuters.com/legal/litigation/hims-offers-apotexs-generic-semaglutide-canada-after-novo-patent-expiry-2026-05-21/
7. The Patent Lawyer Magazine, “The semaglutide saga continues: navigating generic entry in Canada” — https://patentlawyermagazine.com/the-semaglutide-saga-continues-navigating-generic-entry-and-reinforcing-patent-strategies-in-canada
8. Pearce IP, “Generic Semaglutide Launches in India” — https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark
9. CNBC, “India is launching cheap weight-loss drugs, but Novo Nordisk is betting its brands will stay on top” — https://www.cnbc.com/2026/03/23/novo-nordisk-cheap-weight-loss-drugs-india-generic-ozempic-wegovy-semaglutide.html
10. ThePrint, “Rs 325-4,200/month: Dr Reddy’s, Sun Pharma, Glenmark kick off generic semaglutide price war” — https://theprint.in/india/rs-325-4200-month-dr-reddys-sun-pharma-glenmark-kick-off-generic-semaglutide-price-war/2885525/
11. Reuters, “FDA set to review Sandoz’s generic GLP-1s” — https://www.reuters.com/business/healthcare-pharmaceuticals/fda-set-review-sandozs-generic-glp-1s-2026-06-29
12. Drug Topics, “FDA Accepts Sandoz Applications for Generic Tirzepatide” — https://www.drugtopics.com/view/fda-accepts-sandoz-applications-for-generic-tirzepatide
13. Managed Healthcare Executive, “Teva Launches First Generic GLP-1 Drug for Obesity” — https://www.managedhealthcareexecutive.com/view/teva-launches-first-generic-glp-1-drug-for-obesity
14. SingleCare, “Generic GLP-1 medications: Current and future landscape” — https://www.singlecare.com/blog/generic-glp-1
15. Meto, “Semaglutide Patent Expiry: What Biosimilars Mean for You” — https://meto.co/blog/semaglutide-patent-expiry-biosimilar
16. The White House, Fact Sheet on most-favored-nation pricing agreements — https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients
17. Drugs.com, “How much does Foundayo cost?” — https://www.drugs.com/medical-answers/how-foundayo-cost-3582156/
18. Fierce Pharma, “The Oral GLP-1 Tracker” — https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill
19. Teva, “Teva Announces FDA Approval and Launch of Generic Saxenda (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss” — https://www.tevausa.com/news-and-media/press-releases/teva-announces-fda-approval-and-launch-of-generic-saxenda-liraglutide-injection—first-generic-glp-1-/
20. Novo Nordisk, “Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus” — https://www.prnewswire.com/news-releases/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-semaglutide-medicines-building-on-continued-efforts-to-expand-access-302695705.html
21. Health Canada, “Canada becomes the first G7 country to approve a generic version of semaglutide” — https://www.canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html
22. Health Canada, “Canada approves first generic semaglutide for weight loss” — https://www.canada.ca/en/health-canada/news/2026/06/canada-approves-first-generic-semaglutide-for-weight-loss.html
23. NovoCare, Wegovy cost and coverage pricing table — https://www.novocare.com/patient/medicines/wegovy.html
24. LillyDirect, Foundayo self-pay pricing — https://www.lilly.com/lillydirect/foundayo